Immunotherapy of malignant ascites with trifunctional antibodies
نویسندگان
چکیده
منابع مشابه
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
A few tumor antigen (TA)-specific monoclonal antibodies (mAb) have been approved by the Food and Drug Administration for the treatment of several major malignant diseases and are commercially available. Once in the clinic, mAbs have an average success rate of approximately 30% and are well tolerated. These results have changed the face of cancer therapy, bringing us closer to more specific and ...
متن کامل1521pintraperitoneal Application of the Trifunctional Monoclonal Antibody Catumaxomab in Outpatients with Malignant Ascites Related to Various Epithelial Tumors.
Aim: Catumaxomab (CATU) is a trifunctional monoclonal antibody approved in the European community for the treatment (Tx) of malignant ascites (MA) related to various carcinomas expressing the epithelial cell adhesion molecule (EpCAM). Recently, the majority of CATU treatments is performed in a hospital. We report on our single-institution experience with an outpatient CATU Tx in patients (pts) ...
متن کاملRenal cell carcinoma presenting with malignant ascites
It is rare for renal cell carcinoma to involve the peritoneum and cause malignant ascites. Furthermore, it is uncommon for malignant ascites to be a presenting feature of this cancer. An unusual case of renal cell carcinoma presenting with malignant ascites is reported, and its response to sunitinib described.
متن کاملPseudomonas aeruginosa keratitis: passive immunotherapy with antibodies raised against divalent flagellin
Objective(s): Pseudomonas aeruginosa infections such as keratitis are considered among the major health problems worldwide due to the complexity of pathogenesis and antibiotic resistance crisis, thus, finding new effective approaches for prevention and treatment of the infections seem to be still vital. In this report, we aimed to investigate the therapeutic effects of topical administration of...
متن کاملImmunotherapy for malignant glioma
Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12-15 months. Moreover, conventional treatment, which includes surgery followed by radiation and chemotherapy, can be highly toxic by causing nonspecific damage to healthy brain and other tissues. The shortcoming...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Cancer
سال: 2005
ISSN: 0020-7136,1097-0215
DOI: 10.1002/ijc.21165